RxDoctor Payments Data

Flavia Fedeles, MD

Dermatology · Wellesley, MANPI 1376851972

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. UCB, Inc. accounts for 61.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $602, more than ten times the $14 reported in 2022. That places this record below the midpoint for dermatology clinicians in MA, where the typical reported total is $979.

$693in general payments, 2019–2025

Across 18 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$427
  • AbbVie$133
  • Sanofi$36
  • Botanix SB Inc$26
  • Arcutis Biotherapeutics, Inc.$24
  • Strata Skin Sciences, Inc.$17
  • plus $29 from 2 others
$15in research payments, 2019–2025

Across 1 payment — averaging $15.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$15

What the payments were for

  • Food & beverage$67998%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.7$427
AbbVie5$133
Sanofi1$36
Botanix SB Inc1$26
Arcutis Biotherapeutics, Inc.1$24
Strata Skin Sciences, Inc.1$17
Lilly USA, LLC1$15
Dermavant Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$693 in reported general payments places this provider in the 40th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$94,461
Medicare patients
442
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$356,445
Dupixent SyringeDupilumab26$113,043
OtezlaApremilast16$76,008
Dupixent PenDupilumab21$75,608
Clobetasol Propionate60$4,175
Ketoconazole97$1,763
Pimecrolimus13$1,226
Triamcinolone Acetonide93$1,021
Betamethasone Dipropionate20$959
Econazole Nitrate20$919
Metronidazole17$772
Fluorouracil16$763
Fluocinonide15$740
Nystatin33$714
Doxycycline Monohydrate26$549

Paid to pharmacies, not to this prescriber.

Other dermatology in Wellesley

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →